Skip to Content

Rule

Designation of Oripavine as a Basic Class of Controlled Substance; Correction

A Rule by the Drug Enforcement Administration on 12/10/2007

Document Details

Information about this document as published in the Federal Register.

Printed version:
PDF
Publication Date:
12/10/2007
Agencies:
Drug Enforcement Administration
Dates:
Effective December 10, 2007.
Effective Date:
12/10/2007
Document Type:
Rule
Document Citation:
72 FR 69618
Page:
69618 (1 page)
CFR:
21 CFR 1308
Agency/Docket Number:
Docket No. DEA-309F
Document Number:
E7-23759
Document Details
Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Page views:
19
as of 10/15/2019 at 10:15 pm EDT
Document Statistics
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Drug Enforcement Administration (DEA), Justice.

ACTION:

Final rule; correcting amendments.

SUMMARY:

On September 24, 2007, the Drug Enforcement Administration (DEA) published in the Federal Register a final rule (72 FR 54208) designating oripavine (3-O-demethylthebaine or 6,7,8,14-tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methylmorphinan-3-ol) as a basic class in schedule II of the Controlled Substances Act (CSA). The drug code for oripavine was inadvertently designated as 9335, a drug code which is already used to identify a schedule I controlled substance. This correction corrects that error and assigns a different drug code to oripavine.

DATES:

Effective December 10, 2007.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Christine A. Sannerud, PhD, Chief, Drug and Chemical Evaluation Section, Drug Enforcement Administration, Washington, DC 20537, by e-mail, ode@dea.usdoj.gov or by fax, (202) 353-1263.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

On September 24, 2007, the Drug Enforcement Administration (DEA) published a Final Rule in the Federal Register (72 FR 54208) designating oripavine (3- O-demethylthebaine or 6,7,8,14-tetradehydro-4,5-alpha-epoxy-6-methoxy-17-methylmorphinan-3-ol) as a basic class in schedule II of the Controlled Substances Act (CSA). In the final rule, the drug code for oripavine was inadvertently listed as 9335. This is the drug code for the schedule I controlled substance, drotebanol. Upon publication of this rule, the drug code for oripavine will be amended to 9330.

Start Amendment Part

Accordingly,

End Amendment Part Start Part

PART 1308—SCHEDULES OF CONTROLLED SUBSTANCES

End Part Start Amendment Part

1. The authority citation for part 1308 continues to read as follows:

End Amendment Part Start Authority

Authority: 21 U.S.C. 811, 812, 871(b), unless otherwise noted.

End Authority Start Amendment Part

2. Section 1308.12(b)(1) is amended by revising the entry (xii) to read as follows:

End Amendment Part
Schedule II.
* * * * *

(b) * * *

(1) * * *

* * * * *
(xii) Oripavine9330
* * * * *
Start Signature

Dated: November 26, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control.

End Signature End Supplemental Information

[FR Doc. E7-23759 Filed 12-7-07; 8:45 am]

BILLING CODE 4410-09-P

Published Document